Three-year study will test biopsy analysis tool shown in trials to identify men likely to benefit from certain drugs
A tool that uses artificial intelligence to help diagnose men with prostate cancer and guide decisions about treatment is to be tested in NHS hospitals, researchers have announced.
The £1.9m Vanguard Path study, funded by Prostate Cancer UK and led by researchers at the University of Oxford, is expected to last three years and will test an AI tool called the ArteraAI Prostate Biopsy Assay. In total, biopsies from more than 4,000 men will be used.
The tool, which analyses digitised biopsy images to produce a personalised risk score, has already been shown in clinical trials to identify which men with high-risk prostate cancer would be most likely to benefit from the drug abiraterone.
However, trials in the US have suggested it could also be used for less aggressive forms of prostate cancer to predict which men are most likely to benefit from having hormone therapy in addition to radiotherapy.
